Esaote Launches PAM Technology, MyLab E85 GTS
Analysis based on 12 articles · First reported Mar 13, 2026 · Last updated Mar 13, 2026
The launch of Esaote's new urological imaging technology, including PAM and new ultrasound systems, is expected to positively impact the medical imaging and healthcare technology markets. It reinforces Esaote's position as an innovator and provider of advanced solutions for prostate care, potentially increasing its market share and revenue.
Esaote, a leading Italian innovator in medical imaging, is reinforcing its position as a provider of advanced imaging and guided therapy solutions for urologists at the 41st Annual European Association of Urology Congress in United Kingdom===London. Esaote is presenting its new and innovative Prostate Attention Map (PAM) technology, which offers automatic analysis of prostate mpMRI volumes and identifies suspicious regions of interest to assist urologists in target guidance and decision-making. PAM Technology is fully integrated into Esaote's UroFusion software. Additionally, Esaote is launching two new urology-dedicated ultrasound systems, MyLab E85 GTS and MyLab C30 GTS, extending high image quality performance. This marks a significant expansion of Esaote's Guided Therapy Solutions (GTS) line, highlighting the company's commitment to empowering urologists with reliable, intelligent, and clinically relevant imaging solutions.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard